COVID-19 Vaccine Text Outreach

NCT04834726 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 19554

Last updated 2023-03-27

Study results available
· View outcomes & findings →

Summary

This project aims to evaluate different approaches to increase COVID-19 vaccine uptake among at-risk patients at Penn Medicine in an equitable and systematic manner through a centralized outreach program. The investigators will evaluate different text-based scheduling and messaging approaches informed by behavioral science to increase uptake among eligible patients, including the use of clinician endorsement, opt-out framing, and scarcity.

Conditions

  • Covid19

Interventions

BEHAVIORAL

Opt-In (Call-Back)

Messaging will include a prompt to agree to scheduling. If patient agrees, the access center will call these patients back to schedule, calling up to 3 times.

BEHAVIORAL

Opt-in (In-Bound)

Messaging will include a prompt to agree to scheduling followed by a prompt to call the Penn Medicine Vaccine Scheduling Hotline to schedule their vaccine appointment.

BEHAVIORAL

Standard Message

The message describes that the patient is eligible for the COVID vaccine.

BEHAVIORAL

Clinician Endorsement

The message will describe an endorsement from the provider to get the vaccination.

BEHAVIORAL

Scarcity

The message will highlight the limited availability and the elevated priority for the patient to receive the vaccine at Penn Medicine.

BEHAVIORAL

Opt-Out Framing

This will highlight that a vaccine is reserved for the patient, implying that they need to opt-out.

BEHAVIORAL

Phone Call

The access center will call these patients to schedule their vaccine appointment. These patients will not receive text messaging.

Sponsors & Collaborators

Principal Investigators

  • Shivan Mehta, MD · University of Pennsylvania

Study Design

Allocation
RANDOMIZED
Purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE
Model
FACTORIAL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-29
Primary Completion
2021-06-04
Completion
2021-07-06

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04834726 on ClinicalTrials.gov